| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.1 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.28 | 0.1 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.047 | 0.1 |